Remifentanil is the newest addition to the company’s extensive portfolio of anesthesia and analgesia products. Remifentanil is a controlled substance sold only to licensed health care professionals for patient care and is distributed under strict controls in compliance with FDA and DEA regulations.

Bortezomib for intravenous use is the first and only available alternative to Bortezomib for Injection and is the newest addition to the company’s expanding oncology portfolio. 

Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.

Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.

Fresenius Kabi opened the extension of its production plant in Mihla, Germany, today with a festive dedication ceremony attended by Mayor Rainer Laemmerhirt. The healthcare company invested about €10 million in the project.

In the new production hall, employees will make core injection-molded components for pharmaceutical containers, port systems – which enable infusions to be administered as gently as possible, for example during chemotherapy – and medical disposables. The latter include such products as feeding tubes and giving sets, which are routinely used in hospitals to administer infusion therapies, clinical nutrition and intravenous drugs. The extension will enable Fresenius Kabi to produce components it previously had to purchase from suppliers.

At approximately 1,000 square meters (10,700 square feet), the new hall doubles the amount of space available for production activities at the plant in Mihla, a town in the eastern German state of Thuringia. The project also includes an expansion of the plant’s warehouse to hold as many as 2,000 pallets – a more than six-fold increase.

Dr. Christian Hauer, President Medical Devices Division of Fresenius Kabi, said: “Products from Fresenius Kabi are used in the care of chronically and critically ill patients, which makes the highest standards of quality and reliability essential. Our employees in Mihla have been doing outstanding work for many years. I’m delighted that with this extension, we are making our Mihla production location ready for the future.”

Mayor Laemmerhirt praised Fresenius Kabi for its commitment to his community: “I am very happy that Fresenius Kabi, as a globally active company, is investing here in Mihla. This can also be seen as a positive sign for our region and its economic development.”

Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.

Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.

Caspofungin, an antifungal medicine, expands the company's sterile injectable anti-infective portfolio.

Fresenius Kabi celebrated the 20-year anniversary of its Friedberg plant in the state of Hesse today. Since production began in 1997, the Fresenius Kabi site has produced more than two billion bottles and bags with infusion solutions, blood volume substitution agents and liquid drugs. These products are used in the therapy and treatment of critically and chronically ill patients.

The adjoining logistics center is the international hub for the company’s entire product line. Each day employees here fill roughly 2,000 orders. The logistics depot is equipped with a fully automated high-rack warehouse with space for 75,000 pallets. Shipments are assembled and packed in the semi-automated pick-and-drop area. From there they are shipped to wholesalers, pharmacies and hospitals in Germany, and worldwide to national subsidiaries of Fresenius Kabi.

Fresenius Kabi has invested about €150 million in the site – and continues to invest. The next step is expansion of the logistics center in response to increasing volume. The building will be expanded by 4,500 square meters (about 50.000 square feet) at a cost of six million euros. The expansion should be completed by early 2019.

Joachim Arnold, County Commissioner of the Wetterau region, acknowledged the importance of the plant for the region: “Fresenius Kabi has for many years been an important company and major employer. The ongoing investment represents job security and is also a tribute to the quality of this site.”

“We will continue the success story of Fresenius Kabi in Friedberg. The new investment expands the capacity of the logistics center to ship our products throughout the world. This means we can help more patients”, said Dr. Michael Schönhofen, member of the Fresenius Kabi Management Board and President of the Pharmaceuticals Division.

Fresenius Kabi currently employs about 750 people at the production site and logistics center in Friedberg, making it one of the largest employers in the Wetterau region. There are also roughly 40 trainees engaged as, for example, chemistry lab assistants, freight forwarders, logistics service providers and mechatronics technicians.